

Status: Currently Official on 17-Feb-2025  
 Official Date: Official as of 01-Aug-2017  
 Document Type: USP Monographs  
 DocId: GUID-51C3E693-9D76-4603-A77C-511E1BACBE62\_1\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M83744\\_01\\_01](https://doi.org/10.31003/USPNF_M83744_01_01)  
 DOI Ref: 859ra

© 2025 USPC  
 Do not distribute

## Tizanidine Tablets

### DEFINITION

Tizanidine Tablets contain Tizanidine Hydrochloride equivalent to NLT 90.0% and NMT 110.0% of the labeled amount of tizanidine (C<sub>9</sub>H<sub>8</sub>ClN<sub>5</sub>S).

### IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### PROCEDURE

**Solution A:** [Water](#) and [phosphoric acid](#) (44:6)

**Buffer:** 3.5 g/L of [sodium 1-pentanesulfonate](#). Adjust with *Solution A* or [1 N sodium hydroxide](#) to a pH of 3.0.

**Mobile phase:** [Acetonitrile](#) and *Buffer* (20:80)

**Tizanidine related compound A solution:** 0.1 mg/mL of [USP Tizanidine Related Compound A RS](#) in [methanol](#)

**Tizanidine related compound B solution:** 0.1 mg/mL of [USP Tizanidine Related Compound B RS](#) in [methanol](#)

**Tizanidine related compound C solution:** 0.1 mg/mL of [USP Tizanidine Related Compound C RS](#) in [methanol](#)

**System suitability solution:** Transfer 23 mg of [USP Tizanidine Hydrochloride RS](#) to a 100-mL volumetric flask, and add 20 mL of *Mobile phase* and 10 mL each of *Tizanidine related compound A solution*, *Tizanidine related compound B solution*, and *Tizanidine related compound C solution*. Sonicate to dissolve the [USP Tizanidine Hydrochloride RS](#), and dilute with *Mobile phase* to volume.

**Standard solution:** 0.046 mg/mL of [USP Tizanidine Hydrochloride RS](#) in *Mobile phase*

**Sample solution:** Transfer a weighed portion of finely powdered Tablets (NLT 20), equivalent to 20 mg of tizanidine, to a 500-mL volumetric flask. Add 250 mL of *Buffer* solution, sonicate for 15 min with occasional shaking, and shake by mechanical means for 15 min. Add 100 mL of [acetonitrile](#), and mix. Allow to cool, and dilute with *Buffer* solution to volume. Centrifuge a portion of this solution at 2000 rpm or higher for 10 min. Pass a portion of this solution through a filter with a 0.45-µm or finer pore size, and use the filtrate.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 230 nm. For *Identification B*, use a diode array detector in the range of 210–400 nm.

**Column:** 4.6-mm × 25-cm; 5-µm packing [L1](#)

**Column temperature:** 50°

**Flow rate:** 1 mL/min

**Injection volume:** 10 µL

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—The relative retention times are listed in [Table 1](#).]

#### Suitability requirements

**Resolution:** NLT 4.0 between tizanidine and tizanidine related compound C; NLT 4.0 between tizanidine and tizanidine related compound B, *System suitability solution*

**Tailing factor:** NMT 2.0, *Standard solution*

**Relative standard deviation:** NMT 2.0%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of tizanidine (C<sub>9</sub>H<sub>8</sub>ClN<sub>5</sub>S) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_S$  = concentration of [USP Tizanidine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of tizanidine in the *Sample solution* (mg/mL)

$M_{r1}$  = molecular weight of tizanidine, 253.71

$M_{r2}$  = molecular weight of tizanidine hydrochloride, 290.17

**Acceptance criteria:** 90.0%–110.0%

## PERFORMANCE TESTS

### • [DISSOLUTION \(711\)](#)

#### Test 1

**Medium:** [0.1 N hydrochloric acid](#); 500 mL

**Apparatus 1:** 100 rpm

**Time:** 15 min

**Solution A, Buffer, and Mobile phase:** Prepare as directed in the Assay.

**Standard solution:**  $(L/500)$  mg/mL of [USP Tizanidine Hydrochloride RS](#) in *Medium*, where  $L$  is the label claim, in mg

**Sample solution:** Sample per [Dissolution \(711\)](#). Dilute with *Medium* to a concentration that is similar to the *Standard solution*.

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 230 nm

**Column:** 4.6-mm × 25-cm; 5- $\mu$ m packing [L1](#)

**Column temperature:** 50°

**Flow rate:** 1 mL/min

**Injection volume:** 20  $\mu$ L

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 2.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of tizanidine ( $C_9H_8ClN_5S$ ) dissolved:

$$\text{Result} = (r_U/r_S) \times C_S \times V \times (1/L) \times (M_{r1}/M_{r2}) \times 100$$

$r_U$  = peak response of tizanidine from the *Sample solution*

$r_S$  = peak response of tizanidine from the *Standard solution*

$C_S$  = concentration of [USP Tizanidine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$V$  = volume of dissolution *Medium*, 500 mL

$L$  = label claim, in mg

$M_{r1}$  = molecular weight of tizanidine, 253.71

$M_{r2}$  = molecular weight of tizanidine hydrochloride, 290.17

**Tolerances:** NLT 80% (Q) of the labeled amount of tizanidine ( $C_9H_8ClN_5S$ ) is dissolved.

#### Test 2

[NOTE—If the product complies with this test, the labeling indicates that the product meets USP *Dissolution Test 2*.]

**Medium:** [0.1 N hydrochloric acid](#); 500 mL, deaerated

**Apparatus 1:** 100 rpm

**Time:** 30 min

**Standard solution:** ( $L/500$ ) mg/mL of [USP Tizanidine Hydrochloride RS](#) in *Medium*, where  $L$  is the label claim, in mg

**Sample solution:** Pass a portion of the solution under test through a suitable filter of 0.45- $\mu$ m pore size.

**Instrumental conditions**

(See [Ultraviolet-Visible Spectroscopy \(857\)](#).)

**Mode:** UV

**Analytical wavelength:** 228 nm

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of tizanidine ( $C_9H_8ClN_5S$ ) dissolved:

$$\text{Result} = (A_U/A_S) \times C_S \times V \times (1/L) \times (M_{r1}/M_{r2}) \times 100$$

$A_U$  = absorbance of the *Sample solution*

$A_S$  = absorbance of the *Standard solution*

$C_S$  = concentration of [USP Tizanidine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$V$  = volume of dissolution *Medium*, 500 mL

$L$  = label claim, in mg

$M_{r1}$  = molecular weight of tizanidine, 253.71

$M_{r2}$  = molecular weight of tizanidine hydrochloride, 290.17

**Tolerances:** NLT 80% (Q) of the labeled amount of tizanidine ( $C_9H_8ClN_5S$ ) is dissolved.

**IMPURITIES**

• **ORGANIC IMPURITIES**

**Solution A, Buffer, Mobile phase, System suitability solution, Standard solution, Chromatographic system, and System suitability:** Proceed as directed in the Assay.

**Sample solution:** Transfer a weighed portion of finely powdered Tablets (NLT 20), equivalent to 20 mg of tizanidine, to a 100-mL volumetric flask. Add about 50 mL of *Buffer* solution, sonicate for about 15 min with occasional shaking, and shake by mechanical means for 15 min. Add 20 mL of [acetonitrile](#), and mix. Allow to cool, dilute with *Buffer* solution to volume, and mix. Centrifuge a portion of this solution at 2000 rpm or higher for 10 min. Pass a portion of this solution through a filter with a 0.45- $\mu$ m or finer pore size, and use the filtrate.

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times (1/F) \times 100$$

$r_U$  = peak response of each impurity from the *Sample solution*

$r_S$  = peak response of tizanidine from the *Standard solution*

$C_S$  = concentration of [USP Tizanidine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of tizanidine in the *Sample solution* (mg/mL)

$M_{r1}$  = molecular weight of tizanidine, 253.71

$M_{r2}$  = molecular weight of tizanidine hydrochloride, 290.17

$F$  = relative response factor (see [Table 1](#))

**Acceptance criteria:** See [Table 1](#).

**Table 1**

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Tizanidine related compound C <sup>a</sup>	0.8	–	–
Tizanidine	1.0	–	–
Tizanidine related compound B <sup>a</sup>	1.4	–	–
Tizanidine related compound A	10.2	1.1	0.2
Any unspecified degradation product	–	1.0	0.2
Total impurities	–	–	0.5

<sup>a</sup> Process impurity included for peak identification purposes only. Controlled in the drug substance.

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers, and store at controlled room temperature.
- **LABELING:** When more than one *Dissolution* test is given, the labeling states the test used only if *Test 1* is not used.

- **USP REFERENCE STANDARDS (11).**

[USP Tizanidine Hydrochloride RS](#)

[USP Tizanidine Related Compound A RS](#)

4-Amino-5-chloro-2,1,3-benzothiadiazole.

$C_6H_4ClN_3S$  185.63

[USP Tizanidine Related Compound B RS](#)

*N*-Acetyltizanidine.

$C_{11}H_{10}ClN_5OS$  295.75

[USP Tizanidine Related Compound C RS](#)

1-Acetylimidazolidine-2-thione.

$C_5H_8N_2OS$  144.19

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
TIZANIDINE TABLETS	<a href="#">Documentary Standards Support</a>	SM42020 Small Molecules 4
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM42020 Small Molecules 4

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 42(2)

**Current DocID:** [GUID-51C3E693-9D76-4603-A77C-511E1BACBE62\\_1\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M83744\\_01\\_01](https://doi.org/10.31003/USPNF_M83744_01_01)

**DOI ref:** [859ra](#)